Technology areas: Biotechnology & Pharmaceuticals • Communications
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Mackay Memorial Hospital currently manages a patent portfolio in the Biotechnology & Pharmaceuticals technology area, featuring 2 pending office actions. These actions are distributed across 2 distinct examiners, indicating a balanced workload for the hospital's active patent applications. This arrangement suggests that the hospital is pursuing multiple technological paths within the biological sector, each subject to independent review by different examiners.
The prosecution is occurring across 2 distinct art units, which indicates that the 2 pending office actions involve different technical classifications within Biotechnology & Pharmaceuticals. CRAIGO, BAHAR ALAWI is the busiest examiner for the portfolio, currently responsible for 1 pending office action. Since the total number of pending office actions is 2, the workload is split between the 2 distinct examiners, with no 1 examiner dominating the prosecution process.
Practitioners should note that the involvement of 2 distinct art units and 2 distinct examiners requires a flexible approach to patent prosecution. The success of the Biotechnology & Pharmaceuticals portfolio is not tied to a single individual, as CRAIGO, BAHAR ALAWI only manages 1 pending office action. This distribution provides a level of variety in the feedback the hospital receives from the patent office across its 2 active matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 1 | 47.3% | +27.2% |
| BLACKSTEN, SYDNEY LYNN | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704869 | USE OF ISORHOIFOLIN AND DERIVATIVE THEREOF IN PROMOTING NERVE REPAIR | CRAIGO, BAHAR ALAWI | — |
| 18411061 | METHODS AND MODLES FOR IDENTIFYING BREAST LESIONS | BLACKSTEN, SYDNEY LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704869 | USE OF ISORHOIFOLIN AND DERIVATIVE THEREOF IN PROMOTING NERVE REPAIR | CRAIGO, BAHAR ALAWI | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 2674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18704869 | USE OF ISORHOIFOLIN AND DERIVATIVE THEREOF IN PROMOTING NERVE REPAIR | CRAIGO, BAHAR ALAWI | 1699 | §102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18411061 | METHODS AND MODLES FOR IDENTIFYING BREAST LESIONS | BLACKSTEN, SYDNEY LYNN | 2674 | §103§112Other | Final Rejection | — | Pending | Jan 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMackay Memorial Hospital has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bahar Alawi Craigo has the most, with 1 of Mackay Memorial Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
